LIFEVANTAGE CORP Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
LIFEVANTAGE CORP (LFVN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 0 shares for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-27.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-08-27
- LIFEVANTAGE CORP share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2026 was 0.00 shares.
- LIFEVANTAGE CORP share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2025 was 0.00 shares.
- LIFEVANTAGE CORP share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2024 was 0.00 shares, a 100.00% decline from fiscal 2023.
- LIFEVANTAGE CORP share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2023 was 20.00K shares, a 62.96% decline from fiscal 2022.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|
| 2026-06-30 | 0.00 shares 10-K · filed 2026-08-27 |
| 2025-06-30 | 0.00 shares 10-K · filed 2026-08-27 |
| 2024-06-30 | 0.00 shares 10-K · filed 2025-09-04 |
| 2023-06-30 | 20.00K shares 10-K · filed 2024-08-28 |
| 2022-06-30 | 54.00K shares 10-K · filed 2023-08-28 |
| 2021-06-30 | 9.00K shares 10-K · filed 2022-08-23 |
| 2020-06-30 | 5.00K shares 10-K · filed 2022-08-23 |
| 2019-06-30 | 29.00K shares 10-K · filed 2021-08-19 |
| 2013-06-30 | 0.00 shares 10-K · filed 2013-09-12 |
| 2012-06-30 | 0.00 shares 10-K · filed 2013-09-12 |
| 2011-06-30 | 0.00 shares 10-K · filed 2013-09-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |